Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.

Described herein are compositions and methods for reducing the variability of inter-sample analyte measurements from a biological matrix. In some embodiments, the present disclosure relates to methods for reducing the variability in the inter-sample levels of one or more proteins from a biological sample as measured by a proteomic assay.

Methods and reference compositions for quantifying protein using tagged standards. In an exemplary method, a reference composition and a protein may be electrophoresed in respective lanes of a gel. The reference composition may include quantitation standards of different size and each including a tag present at a different concentration. The quantitation standards and the protein may be transferred from the gel to a solid support to create a blot. Luminescence may be detected from the blot to obtain respective luminescence values separately representing an abundance of the tag of each quantitation standard and an abundance of the protein. A quantity of the protein may be determined using the respective luminescence values.

Pre-treatment clinical data and radiomic features extracted from computed tomography (CT) scans were used to develop a parsimonious model to predict survival outcomes among NSCLC patients treated with immunotherapy. The biological underpinnings of the radiomics features were assessed utilizing geneexpression information from a well-annotated radiogenomics NSCLC dataset and were further assessed for survival in four independent NSCLC cohorts. Therefore, disclosed herein is a method for predicting efficacy of immunotherapy in a subject with lung cancer using the disclosed radiomic features.

Systems and methods for tracking healing progress of multiple adjacent wounds are provided. In one embodiment, a system may include a processor configured to receive a first image of a plurality of adjacent wounds near a form of colorized surface having colored reference elements, determine colors of the plurality of wounds, correct for local illumination conditions, receive a second image of the plurality of wounds near the form of colorized surface, to determine second colors of the plurality of wounds in the second image, match each of the plurality of wounds in the second image to a wound of the plurality of wounds in the first image, and determine an indicator of the healing progress for each of the plurality of wounds based on changes between the first image and the second image.

The present invention provides biomarkers of oxidative stress in subjects with retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Fuchs' dystrophy, diabetic macular edema (DME), geographic atrophy, Stargardt's disease, or retinal vein occlusion (RVO), and their use in identifying subjects in need of treatment and methods for staging the severity of the disease.

A lateral flow assay device for testing a biological sample includes housing, a sample receiving pad, a conjugate test pad, and a nitrocellulose membrane. The sample receiving pad and conjugate test pad, as well as the nitrocellulose membrane, are enclosed within an interior portion of the housing. The sample receiving pad is in fluid communication with an opening defined in an outer surface of the housing for receiving the biological sample. At least a portion of the conjugate test pad is in contact with the sample receiving pad and is configured to test the biological sample. At least one window is defined in the outer surface of the housing adjacent the conjugate test pads such that the results of the test performed on the conjugate test pads are visible from outside of the housing.

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R.sup.1 and R.sup.2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I′), which is: R1′-X′—R2′, in which either the moeities R1′ or R2′ or X′ carry a drug that is covalently attached to the diboron compound.

Systems and methods for tracking healing progress of multiple adjacent wounds are provided. In one embodiment, a system may include a processor configured to receive a first image of a plurality of adjacent wounds near a form of colorized surface having colored reference elements, determine colors of the plurality of wounds, correct for local illumination conditions, receive a second image of the plurality of wounds near the form of colorized surface, to determine second colors of the plurality of wounds in the second image, match each of the plurality of wounds in the second image to a wound of the plurality of wounds in the first image, and determine an indicator of the healing progress for each of the plurality of wounds based on changes between the first image and the second image.